Ozempic, Wegovy, and Rybelsus are three different brand names for the same active molecule: semaglutide. Novo Nordisk markets them differently because regulatory indications, dose ranges, and routes of administration differ. From a research perspective, knowing what separates them clarifies the published trial data and avoids confusion.
The shared molecule
All three contain semaglutide — a long-acting GLP-1 receptor agonist with a ~7-day plasma half-life. The molecular structure is identical across the brands. What differs is dose strength, route, and approved use.
Ozempic — the diabetes brand
| Attribute | Detail |
|---|---|
| Indication | Type 2 diabetes |
| Route | Subcutaneous injection, weekly |
| Dose range | 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg weekly |
| Trial programme | SUSTAIN (diabetes endpoints) |
The maximum approved dose for Ozempic is 2.0 mg weekly. Weight loss is a documented side effect but not the primary endpoint.
Wegovy — the weight-management brand
| Attribute | Detail |
|---|---|
| Indication | Chronic weight management in obesity |
| Route | Subcutaneous injection, weekly |
| Dose range | 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly |
| Trial programme | STEP (weight-loss endpoints) |
Wegovy reaches a higher maximum dose (2.4 mg) than Ozempic. The STEP trial programme established the ~14.9% weight loss endpoint that drives the brand’s positioning.
Rybelsus — the oral tablet
| Attribute | Detail |
|---|---|
| Indication | Type 2 diabetes |
| Route | Oral tablet, daily |
| Dose range | 3 mg → 7 mg → 14 mg daily |
| Trial programme | PIONEER |
Rybelsus is the only oral GLP-1 agonist on the market. Oral bioavailability of peptides is normally near-zero — Rybelsus solves this with a co-formulated absorption enhancer (SNAC, sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) that opens gastric tight junctions. Bioavailability remains low (~1%), which is why oral doses are 14 mg versus subcutaneous 2.4 mg.
Why the same molecule needs three brands
Regulatory approvals in many countries are indication-specific. A medication approved for diabetes cannot be marketed for weight loss without a separate trial programme and approval. Novo Nordisk ran the SUSTAIN trials for diabetes (→ Ozempic, oral version → Rybelsus) and the STEP trials for weight management (→ Wegovy). Same molecule, three approved use cases, three brand names.
Practical research implications
For researchers studying semaglutide:
- Subcutaneous research at weight-management-equivalent doses references the 2.4 mg weekly endpoint
- Subcutaneous research at diabetes-equivalent doses uses the 1–2 mg range
- Oral research is conceptually distinct — bioavailability limits create different pharmacokinetic profiles
What this means for catalogue listings
Research peptide catalogues list “semaglutide” — the molecule. The brand names are regulatory and marketing constructs. Chempeptides supplies HPLC-verified semaglutide with batch CoA — see the catalogue for current availability and the Ozempic mechanism article for trial data depth.
Research use only.